Sulindac metabolism and synergy with tumor necrosis factor-α in a drug-inflammation interaction model of idiosyncratic liver injury

Journal of Pharmacology and Experimental Therapeutics

Volumn 331, Issue 1, 2009, Pages 114-121

  Zou, Wei ^a,b   Beggs, Kevin M ^b,c   Sparkenbaugh, Erica M ^b,c   Jones, A Daniel ^b,c,d   Younis, Husam S ^e   Roth, Robert A ^b,c   Ganey, Patricia E ^b,c  

^a Michigan State University ^*  (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

^d Michigan State University   (United States)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; ETANERCEPT; LIPOPOLYSACCHARIDE; SULFIDE; SULFONE; SULINDAC; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; LIVER CELL; LIVER INJURY; LIVER TOXICITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TANDEM MASS SPECTROMETRY;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG-INDUCED LIVER INJURY; HUMANS; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; LIVER; RATS; RATS, SPRAGUE-DAWLEY; SULINDAC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349330690     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.156331     Document Type: Article

References (34)

1. Adamson GM and Billings RE (1992) Tumor necrosis factor induced oxidative stress in isolated mouse hepatocytes. Arch Biochem Biophys 294:223-229.
2. Adamson GM and Billings RE (1993) Cytokine toxicity and induction of NO synthase activity in cultured mouse hepatocytes. Toxicol Appl Pharmacol 119:100-107. (Pubitemid 23109421)
3. Beg AA and Baltimore D (1996) An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 274:782-784.
4. Bock JM, Menon SG, Goswami PC, Sinclair LL, Bedford NS, Jackson RE, and Trask DK (2007) Differential activity of sulindac metabolites against squamous cell carcinoma of the head and neck is mediated by p21waf1/cip1 induction and cell cycle inhibition. Cancer Biol Ther 6:30-39.
5. Bradham CA, Qian T, Streetz K, Trautwein C, Brenner DA, and Lemasters JJ (1998) The mitochondrial permeability transition is required for tumor necrosis factor alpha-mediated apoptosis and cytochrome c release. Mol Cell Biol 18:6353-6364. (Pubitemid 28500525)
6. Cho JY (2007) Immunomodulatory effect of nonsteroidal anti-inflammatory drugs (NSAIDs) at the clinically available doses. Arch Pharmacol Res 30:64-74.
7. Deng X, Lu J, Lehman-McKeeman LD, Malle E, Crandall DL, Ganey PE, and Roth RA (2008) p38 mitogen-activated protein kinase-dependent tumor necrosis factor-alpha-converting enzyme is important for liver injury in hepatotoxic interaction between lipopolysaccharide and ranitidine. J Pharmacol Exp Ther 326:144-152. (Pubitemid 351872151)
8. Deng X, Luyendyk JP, Zou W, Lu J, Malle E, Ganey PE and Roth RA (2007) Neutrophil interaction with the hemostatic system contributes to liver injury in rats cotreated with lipopolysaccharide and ranitidine. J Pharmacol Exp Ther. 322:852-861.
9. Duggan DE (1981) Sulindac: therapeutic implications of the prodrug/pharmacophore equilibrium. Drug Metab Rev 12:325-337.
10. Duggan DE, Hooke KF, and Hwang SS (1980) Kinetics of the tissue distributions of sulindac and metabolites. Relevance to sites and rates of bioactivation. Drug Metab Dispos 8:241-246.
11. Duggan DE, Hooke KF, Risley EA, Shen TY, and Arman CG (1977) Identification of the biologically active form of sulindac. J Pharmacol Exp Ther 201:8-13.
12. Fernández-Martínez E, Morales-Ríos MS, Pérez-Alvarez V, and Muriel P (2004) Immunomodulatory effects of thalidomide analogs on LPS-induced plasma and hepatic cytokines in the rat. Biochem Pharmacol 68:1321-1329. (Pubitemid 39179390)
13. Ganey PE, Luyendyk JP, Maddox JF, and Roth RA (2004) Adverse hepatic drug reactions: inflammatory episodes as consequence and contributor. Chem Biol Interact 150:35-51.
14. Geier A, Dietrich CG, Voigt S, Kim SK, Gerloff T, Kullak-Ublick GA, Lorenzen J, Matern S, and Gartung C (2003) Effects of proinflammatory cytokines on rat organic anion transporters during toxic liver injury and cholestasis. Hepatology 38:345-354. (Pubitemid 36919855)
15. Gómez-Gaviro MV, González-Alvaro I, Domínguez- Jiménez C, Peschon J, Black RA, Sánchez-Madrid F, and Díaz-González F (2002) Structure-function relationship and role of tumor necrosis factor-alpha-converting enzyme in the down-regulation of L-selectin by non-steroidal anti-inflammatory drugs. J Biol Chem 277:38212-38221.
16. Kaplowitz N (2005) Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 4:489-499.
17. Kim CH, Song KS, Kim KS, Kim JY, Lee BJ, Lee JG, and Yoon JH (2005) Sulindac sulfide-induced apoptosis in sinonasal cancer cells. Acta Otolaryngol 125:201-206. (Pubitemid 40293214)
18. Leite S, Martins NM, Dorta DJ, Curti C, Uyemura SA, and dos Santos AC (2006) Mitochondrial uncoupling by the sulindac metabolite, sulindac sulfide. Basic Clin Pharmacol Toxicol 99:294-299.
19. Luyendyk JP, Shaw PJ, Green CD, Maddox JF, Ganey PE, and Roth RA (2005) Coagulation-mediated hypoxia and neutrophil-dependent hepatic injury in rats given lipopolysaccharide and ranitidine. J Pharmacol Exp Ther 314:1023-1031.
20. O'Connor N, Dargan PI, and Jones AL (2003) Hepatocellular damage from nonsteroidal anti-inflammatory drugs. QJM 96:787-791. (Pubitemid 37369293)
21. Renton KW (2001) Alteration of drug biotransformation and elimination during infection and inflammation. Pharmacol Ther 92:147-163.
22. Roth RA, Luyendyk JP, Maddox JF, and Ganey PE (2003) Inflammation and drug idiosyncrasy - is there a connection? J Pharmacol Exp Ther 307:1-8.
23. Schwabe RF and Brenner DA (2006) Mechanisms of Liver Injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways. Am J Physiol Gastrointest Liver Physiol 290:G583-G589.
24. Shaw PJ, Hopfensperger MJ, Ganey PE, and Roth RA (2007) Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha. Toxicol Sci 100:259-266.
25. Sun Y, Chen J, and Rigas B (2009) Chemopreventive agents induce oxidative stress in cancer cells leading to COX-2 overexpression and COX-2-independent cell death. Carcinogenesis 30:93-100.
26. Tukov FF, Luyendyk JP, Ganey PE, and Roth RA (2007) The role of tumor necrosis factor alpha in lipopolysaccharide/ranitidine-induced inflammatory liver injury. Toxicol Sci 100:267-280. (Pubitemid 47617823)
27. Tukov FF, Maddox JF, Amacher DE, Bobrowski WF, Roth RA, and Ganey PE (2006) Modeling inflammation-drug interactions in vitro: a rat Kupffer cell-hepatocyte coculture system. Toxicol In Vitro 20:1488-1499.
28. Vattanaviboon P, Seeanukun C, Whangsuk W, Utamapongchai S, and Mongkolsuk S (2005) Important role for methionine sulfoxide reductase in the oxidative stress response of Xanthomonas campestris pv. phaseoli. J Bacteriol 187:5831-5836. (Pubitemid 41134321)
29. Watkins PB (2005) Idiosyncratic liver injury: challenges and approaches. Toxicol Pathol 33:1-5.
30. Wullaert A, van Loo G, Heyninck K, and Beyaert R (2007) Hepatic tumor necrosis factor signaling and nuclear factor-kappaB: effects on liver homeostasis and beyond. Endocr Rev 28:365-386. (Pubitemid 46984825)
31. Yamamoto Y, Yin MJ, Lin KM, and Gaynor RB (1999) Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem 274:27307-27314. (Pubitemid 29440083)
32. Yasui H, Adachi M, and Imai K (2003) Combination of tumor necrosis factor-alpha with sulindac augments its apoptotic potential and suppresses tumor growth of human carcinoma cells in nude mice. Cancer 97:1412-1420. (Pubitemid 36297770)
33. Zhang J, Chaluvadi MR, Reddy R, Motika MS, Richardson TA, Cashman JR and Morgan ET (2009) Hepatic flavin-containing monooxygenase gene regulation in different mouse inflammation models. Drug Metab Dispos 37:462-468.
34. Zou W, Devi SS, Sparkenbaugh E, Younis HS, Roth RA, and Ganey PE (2009) Hepatotoxic interaction of sulindac with lipopolysaccharide: role of the hemostatic system. Toxicol Sci 108:184-193.